Zobrazeno 1 - 10
of 119
pro vyhledávání: ''
Autor:
Yoshua Esquenazi, Jay-Jiguang Zhu, Magda Martir, Sigmund H. Hsu, Antonio Dono, Nitin Tandon, Mark Amsbaugh, Richard H. Smilie, Roy Riascos, Dong H. Kim, Leomar Y. Ballester, Angel I. Blanco
Publikováno v:
J Neurooncol
INTRODUCTION: Despite aggressive treatment, glioblastoma invariably recurs. The optimal treatment for recurrent glioblastoma (rGBM) is not well defined. Stereotactic radiosurgery (SRS) for rGBM has demonstrated favorable outcomes for selected patient
Autor:
Maria Antonietta Oliva, Felice Giangaspero, Antonietta Arcella, Sabrina Staffieri, Salvatore Castaldo, Vincenzo Esposito
Publikováno v:
Journal of Neuro-Oncology. 151:123-133
Gliomas represent about 80% of primary brain tumours and about 30% of malignant ones, which today don’t have a resolution therapy because of their variability. A valid model for the study of new personalized therapies can be represented by primary
Autor:
Adebowale J. Adeniran, Thuy Tran, Veronique Neumeister, Lucia B. Jilaveanu, John J. McGuire, Sarah A. Weiss, Christopher R. Zito, Harriet M. Kluger, Kazuki Heishima
Publikováno v:
Journal of Neuro-Oncology
Background Although melanoma brain metastases (MBM) tend to respond to systemic therapy concordantly with extracranial metastases, little is known about differences in immune cell and vascular content between the brain and other metastatic sites. Her
Autor:
Emily Wang, Antonio Dono, Yoshua Esquenazi, Arvind V. Ramesh, Leomar Y. Ballester, Nitin Tandon, Victor Lopez-Rivera
Publikováno v:
Journal of Neuro-Oncology. 148:389-397
Glioblastomas (GBMs) usually occur as a solitary lesion; however, about 0.5–35% present with multiple lesions (M-GBM). The genetic landscape of GBMs have been thoroughly investigated; nevertheless, differences between M-GBM and single-foci GBM (S-G
Autor:
Lisa Stefanie Hönikl, Claire Delbridge, Bernhard Meyer, Jens Gempt, Jürgen Schlegel, Friederike Lämmer
Publikováno v:
Journal of Neuro-Oncology
Introduction Glioblastoma multiforme (GBM) is a highly malignant glial tumor, affecting men more often than women. The reason for this gender-specific predominance remains unclear, raising the question whether these effects are subject to hormonal co
Publikováno v:
Journal of Neuro-Oncology
PurposeEcotropic viral integration site-1 (EVI1) is a transcription factor that contributes to the unfavorable prognosis of leukemia, some epithelial cancers, and glial tumors. However, the biological function of EVI1 in glioblastoma multiforme (GBM)
Autor:
Rekha Chaudhary, Adam L. Cohen, Leping Wan, Stephen Marcus, Prakash Chinnaiyan, Jian Campian, Jiayi Huang, John A. Boockvar, Samuel Goldlust, Karen Fink
Publikováno v:
Journal of Neuro-Oncology. 142:537-544
Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ). A previous phase I study demonstrated the safety of combining DSF
Autor:
Wolfram Schwindt, Oliver Grauer, Matthias Weckesser, Katharina Hess, Mohammed Jaber, Johannes Wölfer, Walter Stummer, Stephan Maring
Publikováno v:
Journal of Neuro-Oncology
Background There is an increasing interest in local tumor ablative treatment modalities that induce immunogenic cell death and the generation of antitumor immune responses. Methods We report six recurrent glioblastoma patients who were treated with i
Autor:
David A. Reardon, Deborah Forst, J. Bryan Iorgulescu, Mary Jane Lim-Fat, Brian M Andersen, Patrick Y. Wen, Kun Wei Song, Isabel Arrillaga-Romany, Elizabeth R. Gerstner, Justin T. Jordan
Publikováno v:
J Neurooncol
PURPOSE: Although uncommon, detection of BRAF V600E mutations in adult patients with glioblastoma has become increasingly relevant given the widespread application of molecular diagnostics and encouraging therapeutic activity of BRAF/MEK inhibitors.
Autor:
Leomar Y. Ballester, Jay-Jiguang Zhu, Yuanqing Yan, Nitin Tandon, Meenakshi B. Bhattacharjee, Yoshua Esquenazi, Antonio Dono, Jennifer Vu, Gabriella Hines, Molly Anapolsky, Takeshi Takayasu
Publikováno v:
J Neurooncol
INTRODUCTION: Recently, the term “Diffuse glioma, BRAF V600E-mutant” has been recommended for IDH-wildtype gliomas with BRAF p.V600E mutation and without CDKN2A/B deletion. However, additional alterations in gliomas that coexist with BRAF-mutatio